Finanzas de Climb Bio Inc (CLYM)CLYMClimb Bio Inc

Evaluating the bottom line, Climb Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -27.10%, provide a clear picture of how effectively CLYM converts its operational activities into shareholder value.

In the context of the broader market, CLYM competes directly with industry leaders such as CRMD and STTK. With a market capitalization of $585.28M, it holds a significant position in the sector. When comparing efficiency, CLYM's gross margin of N/A stands against CRMD's 75.66% and STTK's N/A. Such benchmarking helps identify whether Climb Bio Inc is trading at a premium or discount relative to its financial performance.

Despite significant net income losses, Climb Bio has a strong cash position of $239.2 million, which is expected to fund operations into 2028. The company reported a GAAP EPS of -$0.18 in Q2 2026, indicating ongoing profitability challenges.